1-ethoxymethyl-5-fluorouracil has been researched along with Reticulum Cell-Like Sarcoma, Yoshida in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, K; Imaoka, T; Kawaguchi, T; Kubo, M; Matsui, Y; Miyauchi, S; Utsunomiya, T | 1 |
| Imaoka, T; Kawaguchi, T; Kishi, K; Kiyono, K; Kubo, M; Tatsumi, K; Yamauchi, T; Yanagihara, Y | 1 |
| Fujii, S; Fukushima, M; Imaoka, T; Ohshimo, H; Shimamoto, Y; Shirasaka, T | 1 |
3 other study(ies) available for 1-ethoxymethyl-5-fluorouracil and Reticulum Cell-Like Sarcoma, Yoshida
| Article | Year |
|---|---|
Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Combinations; Drug Interactions; Fluorouracil; Lung; Lung Neoplasms; Male; Neoplasm Transplantation; Pyridines; Rats; Sarcoma, Yoshida; Tegafur; Transplantation, Heterologous; Uracil | 1994 |
3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
Topics: Alanine; Animals; Antineoplastic Agents; Dihydrouracil Dehydrogenase (NAD+); Drug Synergism; Fluorouracil; Male; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Phosphorylation; Pyridines; Rats; Rats, Inbred Strains; Sarcoma, Yoshida; Tumor Cells, Cultured; Uracil | 1993 |
Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Fluorouracil; Mice; Mice, Inbred ICR; Pyridines; Rats; Sarcoma 180; Sarcoma, Yoshida | 1989 |